Clinical Decision Support Tool and Rapid Point-of-Care Platform for Determining Disease Severity in Patients with COVID-19

Michael P McRae; Glennon W Simmons; Nicolaos J Christodoulides; Zhibing Lu; Stella K Kang; David Fenyo; Timothy Alcorn; Isaac P Dapkins; Iman Sharif; Deniz Vurmaz; Sayli S Modak; Kritika Srinivasan; Shruti Warhadpande; Ravi Shrivastav; John T McDevitt

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04. 16.20068411 doi: medRxiv preprint This paper describes the customization of a point-of-care diagnostic tool that is suitable for the measurement of biomarkers that can be used to discriminate between COVID-19 patients that recover vs. those that die from complications of this terrible disease. The work details both the development of a multiparameter protein assay and the diagnostic models that can lend information related to the COVID-19 severity. The model was trained and internally validated using data from 160 hospitalized COVID-19 patients from Wuhan, China 14 and was evaluated on an external case study of 12 hospitalized patients with a spectrum of COVID-19 disease complications from Shenzhen, China. To our knowledge, this effort is the first quantitative pointof-care diagnostic panel linked to a clinical decision support tool that could be used to predict disease severity for patients suffering from COVID-19 infections. In addition to the new point-ofcare diagnostic panel and decision tools, an app is envisioned for immediate release to help clinicians in the next few weeks manage their COVID-19 patients.